RxDoctor Payments Data

Thomas Venditti

Physician Assistant · Amsterdam, NYNPI 1063418457

Payments from drug & device makers

$1,040in general payments, 2019–2025

Across 17 payments — averaging $61.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$382
  • AbbVie$215
  • Novo Nordisk$173
  • Braeburn Inc.$101
  • Pfizer$100
  • GSK$34
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$1,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$382
AbbVie3$215
Novo Nordisk1$173
Braeburn Inc.4$101
Pfizer1$100
GSK1$34
Indivior Inc.1$22
Tolmar, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,040 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$47,770
Medicare patients
129
Services billed
517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$123,426
EliquisApixaban65$74,281
JanuviaSitagliptin Phosphate28$40,824
TradjentaLinagliptin25$25,921
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,991
XareltoRivaroxaban16$21,692
TrulicityDulaglutide13$18,024
JardianceEmpagliflozin18$16,898
RybelsusSemaglutide11$10,383
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$10,274
Breo ElliptaFluticasone/Vilanterol18$8,807
SymbicortBudesonide/Formoterol Fumarate19$8,437
Incruse ElliptaUmeclidinium Bromide24$8,166
MyrbetriqMirabegron18$7,878
JanumetSitagliptin Phos/Metformin Hcl12$6,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$173$133,80997 claims
PfizerEliquis$100$74,28165 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$34$41,96379 claims
AstraZenecaSymbicort$382$8,43719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Amsterdam

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →